Vorasidenib: What is it and what does it mean for you? | Living Well with Brain Cancer

Learn about the latest FDA-approved treatment for low-grade gliomas with mutant IDH1 and IDH2 from UCSF neuro-oncologist, Jennie Taylor, MD. Lynton Daniel offers a first-hand perspective. Introduction by Susan Chang, MD. Sponsored by the UCSF Sheri Sobrato Brain Cancer Survivorship Program.
For more information about the Survivorship Program, visit: braintumorcent...